Skip to main content
. Author manuscript; available in PMC: 2024 Mar 15.
Published in final edited form as: Clin Cancer Res. 2023 Sep 15;29(18):3603–3611. doi: 10.1158/1078-0432.CCR-23-0536

Table 2.

Treatment-related adverse events (TRAE)

TRAE Any Grade, n (%) Grade 3, n (%) Grade 4, n (%)

Lymphopenia 10 (83.3) 4 (33.3) 1 (8.3)
Leukopenia 6 (50.0) 2 (16.7) 0
Diarrhea 6 (50.0) 1 (8.3) 0
Fatigue 6 (50.0) 0 0
Neutropenia 5 (41.7) 3 (25) 0
Anemia 4 (33.3) 0 0
Nausea 4 (33.3) 0 0
Alopecia 4 (33.3) 0 0
Rash 3 (25.0) 0 0
Anorexia 3 (25.0) 0 0
Thrombocytopenia 2 (16.7) 0 0
Vomiting 2 (16.7) 0 0

The following grade 1 TRAEs each occurred in 1 patient: dysgeusia, dyspepsia, bloating, dizziness, hypotension, infusion reaction, constipation